Drug intelligence / Profile preview

goserelin + tamoxifen + zoledronic acid

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Oral, Intravenous

Overview

A combination therapy used in premenopausal women with early-stage, hormone-responsive breast cancer. This regimen combines ovarian suppression through goserelin (Zoladex), hormone therapy with tamoxifen, and the bisphosphonate zoledronic acid. Clinical studies have shown that adding zoledronic acid to hormone therapy with goserelin reduces the risk of cancer relapse by approximately 35% compared to hormone therapy alone.

Targets

ESR1 (ERα)GnRHR (Gonadotropin-releasing hormone receptor)ESR2 (ERβ)FDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on goserelin + tamoxifen + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on goserelin + tamoxifen + zoledronic acid.

Explore the full profile